A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris

J Am Acad Dermatol. 2004 Mar;50(3):443-7. doi: 10.1016/j.jaad.2003.07.021.

Abstract

Excessive sebum production is a central aspect of the pathophysiology of acne vulgaris. Sebaceous gland function is under androgen control and it is hypothesized that dihydrotestosterone is formed by the action of 5 alpha-reductase. Type I is the controlling isoenzyme. This study describes a 3-month, multicenter, randomized, placebo-controlled clinical trial with a potent, selective inhibitor of type I 5 alpha-reductase used alone and in combination with systemic minocycline. Inhibition of type I 5 alpha-reductase was not associated with clinical improvement of acne when used alone and did not enhance the clinical benefit of systemic minocycline. These results indicate the need for further work at the molecular level to better understand the action of androgens on sebaceous gland function.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acne Vulgaris / drug therapy*
  • Cholestenone 5 alpha-Reductase / antagonists & inhibitors*
  • Double-Blind Method
  • Drug Therapy, Combination
  • Humans
  • Minocycline / administration & dosage
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Cholestenone 5 alpha-Reductase
  • Minocycline